Predictive Oncology Stock Current Liabilities
| POAI Stock | USD 0.80 0.02 2.56% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Predictive Oncology's long-term financial health and intrinsic value.
Predictive | Build AI portfolio with Predictive Stock |
Predictive Oncology Company Current Liabilities Analysis
Predictive Oncology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Predictive Oncology has a Current Liabilities of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Predictive Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Predictive Oncology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Predictive Oncology could also be used in its relative valuation, which is a method of valuing Predictive Oncology by comparing valuation metrics of similar companies.Predictive Oncology is currently under evaluation in current liabilities category among its peers.
Predictive Fundamentals
| Return On Equity | -4.9 | ||||
| Return On Asset | -0.73 | ||||
| Operating Margin | (20.73) % | ||||
| Current Valuation | 9.16 M | ||||
| Shares Outstanding | 9.61 M | ||||
| Shares Owned By Insiders | 1.18 % | ||||
| Shares Owned By Institutions | 1.92 % | ||||
| Number Of Shares Shorted | 67.48 K | ||||
| Price To Book | 1.43 X | ||||
| Price To Sales | 4.43 X | ||||
| Revenue | 1.62 M | ||||
| Gross Profit | 880.45 K | ||||
| EBITDA | (10.16 M) | ||||
| Net Income | (10.86 M) | ||||
| Cash And Equivalents | 25.39 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.13 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (10.97 M) | ||||
| Short Ratio | 0.64 X | ||||
| Earnings Per Share | (1.43) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 23 | ||||
| Beta | 1.18 | ||||
| Market Capitalization | 7.65 M | ||||
| Total Asset | 4.97 M | ||||
| Retained Earnings | (180.43 M) | ||||
| Working Capital | (1.37 M) | ||||
| Net Asset | 4.97 M |
About Predictive Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Predictive Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Predictive Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Predictive Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VALE | Vale SA ADR | |
| EGY | Vaalco Energy | |
| CMCSA | Comcast Corp | |
| BTE | Baytex Energy Corp | |
| SOXS | Direxion Daily Semiconductor |
Check out Predictive Oncology Piotroski F Score and Predictive Oncology Altman Z Score analysis. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.